OPCH Stock Analysis: Option Care Health | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 3.439m USD | 12M Return: -29.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 55.5M
EPS Trend: 97.5%
Qual. Beats: 1
Rev. Trend: 99.3%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Option Care Health, Inc. (NASDAQ: OPCH) is a U.S. provider of home and alternate site infusion services, headquartered in Bannockburn, Illinois. The company delivers intravenous and injectable therapies to patients outside of traditional hospital settings.
Its service portfolio includes anti-infective therapy, home infusion for heart failure, parenteral and enteral nutrition for conditions such as stroke, cancer, and gastrointestinal disorders, immunoglobulin therapies for immune deficiencies, and biologic treatments for chronic inflammatory diseases including Crohns disease, ulcerative colitis, rheumatoid arthritis, and plaque psoriasis. It also provides infusion therapies for neurological disorders (such as multiple sclerosis and Duchenne muscular dystrophy), bleeding disorders (including hemophilia and von Willebrand disease), high-risk pregnancies, chemotherapy, pain management, and respiratory medications, along with associated nursing services.
The company generates demand through patient referrals sourced from physicians, hospital discharge planners, hospital personnel, health maintenance organizations (HMOs), and preferred provider organizations (PPOs).
Option Care Health sits within the Health Care Services sub-industry of the broader Health Care sector. The home and alternate site infusion model allows clinically complex therapies to be delivered in lower-cost outpatient settings, a structural trend supported by payer efforts to reduce hospital admissions and length of stay.
- Home infusion demand grows with aging US population
- Medicare reimbursement changes pressure infusion service margins
- Competition from UnitedHealth and CVS specialty pharmacies intensifies
| Net Income: 206.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -3.49 > 1.0 |
| NWC/Revenue: 8.21% < 20% (prev 7.44%; Δ 0.77% < -1%) |
| CFO/TA 0.08 > 3% & CFO 253.6m > Net Income 206.2m |
| Net Debt (1.20b) to EBITDA (411.4m): 2.92 < 3 |
| Current Ratio: 1.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (158.2m) vs 12m ago -5.15% < -2% |
| Gross Margin: 18.00% > 18% (prev 19.71%; Δ -1.71% > 0.5%) |
| Asset Turnover: 169.5% > 50% (prev 156.7%; Δ 12.74% > 0%) |
| Interest Coverage Ratio: 5.59 > 6 (EBIT TTM 341.4m / Interest Expense TTM 61.1m) |
| A: 0.14 (Total Current Assets 1.20b - Total Current Liabilities 729.7m) / Total Assets 3.38b |
| B: 0.27 (Retained Earnings 922.3m / Total Assets 3.38b) |
| C: 0.10 (EBIT TTM 341.4m / Avg Total Assets 3.34b) |
| D: 0.67 (Book Value of Equity 1.35b / Total Liabilities 2.03b) |
| Altman-Z'' = 3.18 = A |
| DSRI: 0.99 (Receivables 516.4m/476.6m, Revenue 5.67b/5.19b) |
| GMI: 1.09 (GM 19.71% / 18.00%) |
| AQI: 0.96 (AQ_t 0.58 / AQ_t-1 0.60) |
| SGI: 1.09 (Revenue 5.67b / 5.19b) |
| TATA: -0.01 (NI 206.2m - CFO 253.6m) / TA 3.38b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 21.57 with a total of 1,802,987 shares traded. Over the past week, the price has changed by -1.51%, over one month by +0.89%, over three months by -25.62% and over the past year by -29.26%.
Current recommended Stop Loss: 20.10 (which is 6.8% or 1.9 ATR below the current price).
Option Care Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy OPCH.
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 28.6 | 32.5% |
P/E Trailing = 17.1094
P/E Forward = 12.3153
P/S = 0.6068
P/B = 2.5465
P/EG = 1.2309
Revenue TTM = 5.67b USD
EBIT TTM = 341.4m USD
EBITDA TTM = 411.4m USD
Long Term Debt = 1.15b USD (from longTermDebt, last quarter)
Short Term Debt = 30.8m USD (from shortTermDebt, last quarter)
Debt = 1.38b USD (from shortLongTermDebtTotal, last quarter) + Leases 110.4m
Net Debt = 1.20b USD (calculated: Debt 1.38b - CCE 177.3m)
Enterprise Value = 4.64b USD (3.44b + Debt 1.38b - CCE 177.3m)
Interest Coverage Ratio = 5.59 (Ebit TTM 341.4m / Interest Expense TTM 61.1m)
EV/FCF = 19.72x (Enterprise Value 4.64b / FCF TTM 235.4m)
FCF Yield = 5.07% (FCF TTM 235.4m / Enterprise Value 4.64b)
FCF Margin = 4.15% (FCF TTM 235.4m / Revenue TTM 5.67b)
Net Margin = 3.64% (Net Income TTM 206.2m / Revenue TTM 5.67b)
Gross Margin = 18.00% ((Revenue TTM 5.67b - Cost of Revenue TTM 4.65b) / Revenue TTM)
Gross Margin QoQ = 18.30% (prev 17.99%)
Tobins Q-Ratio = 1.37 (Enterprise Value 4.64b / Total Assets 3.38b)
Interest Expense / Debt = 4.42% (Interest Expense 61.1m / Debt 1.38b)
Taxrate = 26.45% (74.2m / 280.3m)
NOPAT = 251.1m (EBIT 341.4m * (1 - 26.45%))
Current Ratio = 1.64 (Total Current Assets 1.20b / Total Current Liabilities 729.7m)
Debt / Equity = 1.02 (Debt 1.38b / totalStockholderEquity, last quarter 1.35b)
Debt / EBITDA = 2.92 (Net Debt 1.20b / EBITDA 411.4m)
Debt / FCF = 5.11 (Net Debt 1.20b / FCF TTM 235.4m)
Total Stockholder Equity = 1.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.17% (Net Income 206.2m / Total Assets 3.38b)
RoE = 15.28% (Net Income TTM 206.2m / Total Stockholder Equity 1.35b)
RoCE = 13.65% (EBIT 341.4m / Capital Employed (Equity 1.35b + L.T.Debt 1.15b))
RoIC = 10.03% (NOPAT 251.1m / Invested Capital 2.50b)
WACC = 5.63% (E(3.44b)/V(4.82b) * Re(6.58%) + D(1.38b)/V(4.82b) * Rd(4.42%) * (1-Tc(0.26)))
Discount Rate = 6.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -100.00 | Cagr: -5.04%
[DCF] Terminal Value 73.10% ; FCFF base≈279.6m ; Y1≈245.2m ; Y5≈198.1m
[DCF] Fair Price = 12.59 (EV 3.18b - Net Debt 1.20b = Equity 1.98b / Shares 157.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 97.51 | EPS CAGR: 18.84% | SUE: 1.19 | # QB: 1
Revenue Correlation: 99.31 | Revenue CAGR: 13.83% | SUE: -1.85 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.43 | Chg30d=-10.43% | Revisions=-25% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.48 | Chg30d=-9.61% | Revisions=-25% | Analysts=11
EPS current Year (2026-12-31): EPS=1.84 | Chg30d=-5.16% | Revisions=-25% | GrowthEPS=+7.0% | GrowthRev=+1.1%
EPS next Year (2027-12-31): EPS=2.05 | Chg30d=-0.19% | Revisions=-25% | GrowthEPS=+11.3% | GrowthRev=+7.0%
[Analyst] Revisions Ratio: -57% (up=0, down=4)